[go: up one dir, main page]

ATE360430T1 - Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors - Google Patents

Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors

Info

Publication number
ATE360430T1
ATE360430T1 AT01909186T AT01909186T ATE360430T1 AT E360430 T1 ATE360430 T1 AT E360430T1 AT 01909186 T AT01909186 T AT 01909186T AT 01909186 T AT01909186 T AT 01909186T AT E360430 T1 ATE360430 T1 AT E360430T1
Authority
AT
Austria
Prior art keywords
kidney
directed against
tumor antigen
vaccine specific
tumors
Prior art date
Application number
AT01909186T
Other languages
English (en)
Inventor
Arie Belldegrun
Cho-Lea Tso
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE360430T1 publication Critical patent/ATE360430T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01909186T 2000-02-14 2001-02-13 Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors ATE360430T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18242900P 2000-02-14 2000-02-14
US18263600P 2000-02-15 2000-02-15

Publications (1)

Publication Number Publication Date
ATE360430T1 true ATE360430T1 (de) 2007-05-15

Family

ID=26878083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01909186T ATE360430T1 (de) 2000-02-14 2001-02-13 Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors

Country Status (7)

Country Link
US (5) US7572891B2 (de)
EP (1) EP1255554B1 (de)
AT (1) ATE360430T1 (de)
AU (1) AU2001236967A1 (de)
DE (1) DE60128070T2 (de)
ES (1) ES2286104T3 (de)
WO (1) WO2001060317A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522226A (ja) * 1997-01-31 2001-11-13 リサーチ コーポレイション テクノロジーズ インコーポレイテッド セミ−同種異系細胞での癌の免疫療法
AU2001236967A1 (en) 2000-02-14 2001-08-27 The Regents Of The University Of California Kidney-specific tumor vaccine directed against kidney tumor antigen g-250
US6646209B2 (en) * 2001-04-13 2003-11-11 Pelstar, L.L.C. Beam scale with user friendly features
DE60328477D1 (de) * 2002-04-16 2009-09-03 Univ California Verfahren zur prognose von nierenzellkarzinom und behandlungsauswahl mit carboanhydrase ix
WO2004067029A1 (fr) * 2002-12-27 2004-08-12 Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd. Procede de preparation d'un vaccin et vaccins antitumoraux
CN1548537B (zh) * 2002-12-27 2010-05-05 深圳市源兴生物医药科技有限公司 疫苗制备方法和抗肿瘤疫苗
EP1871166A4 (de) * 2005-03-29 2008-11-12 Univ Illinois Karzinomimpfstoffe und therapeutische verfahren
JP5114418B2 (ja) * 2005-09-09 2013-01-09 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ 細胞死を抑制する又は細胞増殖を高めるための方法及び組成物
KR100825984B1 (ko) * 2006-03-24 2008-04-28 가톨릭대학교 산학협력단 조사된 인간 ｂ형 간염 표면 항원을 발현하는 암세포를이용하여 종양을 치료하는 방법 및 상기 암세포를 포함하는종양치료용 약학적 조성물
WO2007134325A2 (en) * 2006-05-15 2007-11-22 Introgen Therapeutics, Inc. Methods and compositions for protein production using adenoviral vectors
JP2010514422A (ja) 2006-12-22 2010-05-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 新規ｔａａ変種に基づく新たな融合分子
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US20160058856A1 (en) * 2013-04-05 2016-03-03 Kyushu University, National University Corporation Anti-tumor dna vaccine
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
EP3589754B1 (de) 2017-03-01 2023-06-28 F. Hoffmann-La Roche AG Diagnose- und therapieverfahren für krebs
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972353A (en) * 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides
CA2192678C (en) 1994-06-15 2010-12-14 Jan Zavada Mn gene and protein
CA2194228C (en) * 1994-07-07 2001-04-03 Virginia Lee Price Fusion proteins comprising gm-csf and antigens and their expression in yeast
US7250291B1 (en) * 1998-08-07 2007-07-31 Dana-Farber Cancer Institute Tumor antigens and uses thereof
AU2001236967A1 (en) 2000-02-14 2001-08-27 The Regents Of The University Of California Kidney-specific tumor vaccine directed against kidney tumor antigen g-250
EP1673630A4 (de) 2003-10-16 2009-04-29 Inst Virology Mn/ca ix und krebsprognose
JP5653299B2 (ja) 2011-06-09 2015-01-14 株式会社ジャパンディスプレイ 液晶表示装置

Also Published As

Publication number Publication date
US10035981B2 (en) 2018-07-31
EP1255554B1 (de) 2007-04-25
US8741306B2 (en) 2014-06-03
US20180371411A1 (en) 2018-12-27
EP1255554A4 (de) 2004-12-08
DE60128070T2 (de) 2008-01-10
DE60128070D1 (de) 2007-06-06
US20150010587A1 (en) 2015-01-08
US20020058041A1 (en) 2002-05-16
AU2001236967A1 (en) 2001-08-27
US7572891B2 (en) 2009-08-11
WO2001060317A2 (en) 2001-08-23
US9409965B2 (en) 2016-08-09
US20160376556A1 (en) 2016-12-29
US20100129313A1 (en) 2010-05-27
ES2286104T3 (es) 2007-12-01
WO2001060317A3 (en) 2002-05-02
EP1255554A2 (de) 2002-11-13

Similar Documents

Publication Publication Date Title
ATE360430T1 (de) Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
Warren et al. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development
Berzofsky et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer
US11590184B2 (en) Oncolytic rhabdovirus expressing IL12
ES2826480T3 (es) Métodos para predecir la utilidad de neoantígenos para inmunoterapia
Behm et al. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation
Garbe et al. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting
Moschella et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
EA202190587A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
Chamberlain et al. Innovations and strategies for the development of anticancer vaccines
EP1622648A4 (de) Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
Xiang et al. Promising particle-based vaccines in cancer therapy
Lens The role of vaccine therapy in the treatment of melanoma
Schütz et al. Immunooncology in breast cancer: active and passive vaccination strategies
Hrouda et al. Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer
Todryk et al. Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity
Decker et al. Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease
Gulley et al. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver
Chamberlain Prospects for the therapeutic use of anticancer vaccines
Morris et al. Therapeutic cancer vaccines
Pandey et al. Cancer vaccines: a step towards prevention and treatment of cancer
MY162106A (en) Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor.their use in the treatment of cancer.
Yücel Immunological Approach to Lung Cancer Part B: Immunological Therapies for Lung Cancer
ATE332920T1 (de) Nukleinsäureimpfstoff bestehend aus einem fusionsprotein, dass eine adjuvanssequenz von einem planzenvirushüllprotein aufweist
Bhaliya et al. Current Strategies for the Development of a Therapeutic Cancer Vaccine–A Review

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties